A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity
← catalyst calendarSponsored by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics (industry) · GPCR — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
230actual
Sites
39
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-10-28 | actual | When the study began enrolling |
| Primary completion | 2025-10-24 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-07-09 | actual | The whole study's end, after follow-up |
| First posted | 2024-11-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Obesity, Overweight, or Chronic Weight Management
Interventions
- Drug: Aleniglipron or Placebo
- Drug: Aleniglipron or Placebo
- Drug: Aleniglipron or Placebo
- Drug: Aleniglipron
- Drug: Aleniglipron
- Drug: Aleniglipron
- Drug: Aleniglipron
Primary outcomes
what the primary-completion date above is the date OFPercent change in body weight from Baseline to Week 36
measured Baseline and week 36
TEAEs and SAEs
measured Baseline and week 72
AESI
measured Baseline and week 72
Evaluate the safety and tolerability of participants with abnormal laboratory values, including hematology, serum chemistry, and coagulation
measured Baseline and week 72
Evaluate long-term safety and tolerability of aleniglipron as measured through electrocardiograms (including, but not limited to, the measurements of ventricular HR, PR interval, QRS duration, QT interval, and QTcF)
measured Baseline and week 72
Evaluate the safety and tolerability of participants with abnormal vital signs, including blood pressure, heart rate, and temperature
measured Baseline and week 72
Publications
- PMID 42249138 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · GPCR's whole pipeline · Catalyst calendar · Every registered study · What changed